Heqet Therapeutics
Develops groundbreaking genetic medicines to reverse the damage of ischemic heart disease, the leading cause of death worldwide.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | £6.6m | Early VC | |
| Total Funding | 000k | ||
| EUR | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | (77 %) | 72071 % |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | (419751 %) | (2415949 %) | (1583 %) |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Heqet Therapeutics is a pre-clinical stage biotech company dedicated to developing non-coding RNA-based therapies to treat cardiovascular diseases, with a particular focus on acute myocardial infarction, commonly known as a heart attack. The company is rooted in the pioneering research of Prof. Mauro Giacca, a leading figure in cardiovascular sciences. Heqet Therapeutics operates in the biotech and pharmaceutical market, primarily targeting healthcare providers and patients suffering from ischemic heart disease, one of the leading causes of death globally.
The business model revolves around the development and eventual commercialization of therapeutic compounds that stimulate cardiac regeneration by upregulating specific non-coding RNAs. These compounds target multiple pathways, including the Hippo pathway and actin cytoskeleton regulatory proteins, to promote cardiac repair. Revenue generation is anticipated through partnerships, licensing agreements, and eventual sales of approved therapies.
Heqet Therapeutics is committed to advancing its pipeline through rigorous pre-clinical and clinical trials, aiming to bring innovative solutions to a market with significant unmet medical needs.
Keywords: non-coding RNA, cardiac regeneration, myocardial infarction, biotech, cardiovascular diseases, therapeutic compounds, Hippo pathway, ischemic heart disease, healthcare providers, biotechnology.